Below are the disclosed royalties Ligand currently receives or is eligible to receive based on future drug approvals.
| Licensee | Program | Annual Royalty Structure on all Sales |
|---|---|---|
| Amgen (1) | Kyprolis |
1.5% –
Sales up to and including $250M 2.0% – Sales from $250M - $500M 2.5% – Sales in the range of $500M - $750M 3.0% – Sales greater than $750M |
| Acrotech/CASI (1) | Evomela | 20% |
| SAGE (1) | Zulresso | 3% |
| Pfizer (1) | Viviant/Conbriza and Duavee |
0.5% –
Less than $400M 1.5% – Sales from $400M - $1.0B 2.5% – Sales greater than $1.0B |
| Palvella | PTX-022 | 5.0% - 9.8% |
| Travere Therapeutics | Sparsentan | 9% |
| Viking | TR Beta (VK2809 and VK0214) | 3.5% - 7.5% |
| Sermonix | Lasofoxifene | 6.0% - 10.0% |
| Merck | V114 | Low single digit royalty |
| Serum Institute of India | Pnuemosil | Low single digit royalty |
| Corvus | Ciforadenant | Mid-single digit to low-teen |
| Dianomi | Mineral Coated Microparticle | 2.0% - 3.0% |
| GigaGen | OmniAb-GigaGen | Mid-single digit royalty |
| MEI Pharma | ME-344 | Low single digit royalty |
| Melinta | Baxdela | 2.5% |
| Novan | SB206 | 7.0% - 10.0% |
| Nucorion | Various | 4.0% - 9.0% |
| Sedor | CE-Budesonide and CE-Meloxicam |
8.0% –
Less than $25M 10.0% – Sales greater than $25M |
| Sedor | CE-Fosphenytoin | 11% |
| Seelos | Various | 4.0% - 10.0% |
| Takeda | pevonedistat | Low single digit royalty |
| Verona | Ensifentrine (RPL554) | Low to mid-single digit royalty |
| Viking | DGAT-1 | 3.0% - 7.0% |
| Viking | FBPase Inhibitor (VK0612) | 7.5% - 9.5% |
| Viking | Oral EPO | 4.5% - 8.5% |
| Viking | SARM (VK5211) | 7.25% - 9.25% |
| Xi'an Xintong | MB07133 | 6% |
| Xi'an Xintong | Pradefovir | 9% |
